This trial is investigating the effectiveness and side effects of nivolumab (Opdivo) with a dendritic cell vaccine for patients with multiple myeloma (MM). The main outcome of this study would be to see the number of patients that develop an allergic reaction to the treatment. This study is recruiting in Boston, MA, United States.
The details
MM is a type of cancer that affects white blood cells which fight infection and cancer. Often, normal white blood cells are not able to recognize cancer cells and so cannot kill them. Nivolumab is a drug that can help normal white blood cells kill the cancer cells and has been effective for other types of cancer. Dendritic cells (DC) are white blood cells that can help activate other white blood cells. DC vaccines are made to activate normal white blood cells to kill the cancer cells.
The purpose of this study is to see if nivolumab and a DC vaccine against MM are effective at killing cancer cells. The main outcomes of the study are to see if patients with MM develop an allergic reaction to the treatment and how well the treatment works.
Who are they looking for?
This study is recruiting 25 patients with relapsed MM. Patients must be over 18 and have previously received treatment with IMID and proteasome inhibitors. Patients must have good liver and kidney function and meet certain blood cell criteria. Patients must agree to use contraception during the study.
Patients should not have plasma cell leukemia, heart disease, gastrointestinal disorders, systemic lupus erythematosus, rheumatoid arthritis or several other diseases including certain cancers. Patients should not be receiving other experimental treatments, have received anti-PD-1 drugs or immunosuppressants for an organ transplant. Patients with certain infections (such as HIV or Hepatitis B or C) cannot participate. Female patients who are pregnant or breastfeeding cannot participate.
How will it work
All patients in this study will receive nivolumab and injections of a DC vaccine targeting MM.
Patients will be monitored for 2 years to see if they develop side effects to the treatment. Patients will also be monitored for 2 years to see how well the treatment works.
